Compass Pathways Secures FDA NDA Rolling Review Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CMPS?
Source: Newsfilter
Compass Pathways PLC's stock surged by 13.55% as it crossed above the 5-day SMA, reflecting strong investor confidence following the FDA's approval for a rolling submission of its NDA for COMP360.
The FDA has granted Compass a rolling submission and review request for its NDA based on positive Phase 3 data for COMP360, with the final submission on track for Q4 2026, thereby expediting the drug's market entry for treatment-resistant depression. Additionally, Compass reported a significant increase in cash reserves, reaching $466 million, which supports its commercialization efforts. The promising clinical data and the establishment of a strong commercial leadership team further enhance market anticipation for COMP360's launch.
This regulatory milestone not only boosts Compass's market position but also reflects the growing confidence in the efficacy of COMP360, positioning the company favorably for future growth in the mental health sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.620
Low
8.00
Averages
18.43
High
40.00
Current: 10.620
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Pathways to Attend RBC Healthcare Conference
- Conference Participation: Compass Pathways plc will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026, participating in a fireside chat on May 19 at 10:00 am ET, showcasing its innovations in mental health.
- Live Webcast: The event will feature a live audio webcast accessible from the 'Events' page in the Investors section of the Compass website, ensuring investors can stay updated in real-time, enhancing transparency and investor confidence.
- Therapeutic Innovation: Compass Pathways is pioneering a new paradigm in mental health treatment through its investigational COMP360 synthetic psilocybin therapy, which has received Breakthrough Therapy designation from the FDA, indicating its potential in treating treatment-resistant depression.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates a global strategy aimed at accelerating patient access to evidence-based mental health innovations, addressing the needs of patients not helped by existing treatments.
See More
COMPASS Pathways Q1 2026 Earnings Call Insights
- Regulatory Progress Accelerated: COMPASS Pathways confirmed a rolling NDA submission and received a National Priority Voucher in Q1, indicating readiness for launch by year-end, showcasing strong advancements in treatment-resistant depression.
- Clinical Data Highlights: CEO Nath emphasized COMP360's unique advantages of rapid onset and durable efficacy, which no other approved TRD drug offers, potentially enhancing the company's competitive edge in the market.
- FDA Review Timeline Expectations: The awarded National Priority Voucher could shorten the FDA review timeline to 1-2 months, with CCO Englebert noting that nearly 90% of the U.S. population lives in states planning to reschedule COMP360 within 30 days post-approval, further driving launch readiness.
- Strong Financial Position: While specific financial figures were not disclosed, Nath stated that successful financing and warrant exercises have resulted in a robust balance sheet, with cash projected to last well into 2028, ensuring operational stability for the future.
See More
COMPASS Pathways Q1 2026 Earnings Beat Expectations
- Earnings Highlights: COMPASS Pathways reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.15, indicating a positive trend in financial performance despite ongoing losses.
- Cash Position: As of March 31, 2026, the company had $466.0 million in cash and cash equivalents, a significant increase from $149.6 million as of December 31, 2025, demonstrating substantial progress in cash management.
- Debt Increase: The company's debt stood at $50.5 million as of March 31, 2026, up from $31.6 million as of December 31, 2025, reflecting increased financing needs as the company expands its operations.
- Financial Guidance: COMPASS expects its current cash position to be sufficient to fund operating expenses and capital expenditures through 2028, showcasing confidence in its future stability and growth prospects.
See More
Compass Pathways Secures FDA NDA Rolling Review Approval
- Regulatory Acceleration: The FDA has granted Compass a rolling submission and review request for its NDA based on positive Phase 3 data for COMP360, with the final submission on track for Q4 2026, thereby expediting the drug's market entry for treatment-resistant depression.
- Strong Financial Position: Compass reported cash and cash equivalents of $466 million as of Q1 2026, a significant increase from $149.6 million at the end of 2025, ensuring sufficient funding for operations and supporting its commercialization efforts well into 2028.
- Promising Clinical Data: COMP360 has demonstrated significant clinical effects in three large late-stage trials, with 26-week Part B data expected to be released in early Q3 2026, which will further enhance market anticipation and confidence in the drug's efficacy.
- Commercial Readiness: Compass has assembled a highly experienced commercial leadership team and is advancing comprehensive launch preparedness efforts, including education initiatives with key opinion leaders and healthcare providers, ensuring that COMP360 can successfully meet market demands upon launch.
See More
COMPASS Pathways to Announce Q1 Earnings on May 13
- Earnings Announcement: COMPASS Pathways ADS (CMPS) is set to announce its Q1 2023 earnings on May 13 before market open, with a consensus EPS estimate of -$0.45, indicating ongoing challenges in profitability.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen one upward revision and no downward adjustments, reflecting a cautiously optimistic outlook from analysts regarding COMPASS Pathways' future performance, despite the overall negative expectation.
- Market Outlook: The company has reported positive Phase III results for its psilocybin asset in treatment-resistant depression trials, suggesting significant potential value in the mental health sector, which could lay the groundwork for future growth.
- Industry Developments: With Trump signing legislation to expedite PTSD research, COMPASS Pathways is positioned strongly in the rapidly evolving psychedelic market, particularly with its upcoming psychedelic filing, which may attract increased investor interest.
See More
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
Compass Pathways to Attend RBC Healthcare Conference
- Conference Participation: Compass Pathways plc will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026, participating in a fireside chat on May 19 at 10:00 am ET, showcasing its innovations in mental health.
- Live Webcast: The event will feature a live audio webcast accessible from the 'Events' page in the Investors section of the Compass website, ensuring investors can stay updated in real-time, enhancing transparency and investor confidence.
- Therapeutic Innovation: Compass Pathways is pioneering a new paradigm in mental health treatment through its investigational COMP360 synthetic psilocybin therapy, which has received Breakthrough Therapy designation from the FDA, indicating its potential in treating treatment-resistant depression.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates a global strategy aimed at accelerating patient access to evidence-based mental health innovations, addressing the needs of patients not helped by existing treatments.
See More
COMPASS Pathways Q1 2026 Earnings Call Insights
- Regulatory Progress Accelerated: COMPASS Pathways confirmed a rolling NDA submission and received a National Priority Voucher in Q1, indicating readiness for launch by year-end, showcasing strong advancements in treatment-resistant depression.
- Clinical Data Highlights: CEO Nath emphasized COMP360's unique advantages of rapid onset and durable efficacy, which no other approved TRD drug offers, potentially enhancing the company's competitive edge in the market.
- FDA Review Timeline Expectations: The awarded National Priority Voucher could shorten the FDA review timeline to 1-2 months, with CCO Englebert noting that nearly 90% of the U.S. population lives in states planning to reschedule COMP360 within 30 days post-approval, further driving launch readiness.
- Strong Financial Position: While specific financial figures were not disclosed, Nath stated that successful financing and warrant exercises have resulted in a robust balance sheet, with cash projected to last well into 2028, ensuring operational stability for the future.
See More
COMPASS Pathways Q1 2026 Earnings Beat Expectations
- Earnings Highlights: COMPASS Pathways reported a Q1 GAAP EPS of -$0.30, beating expectations by $0.15, indicating a positive trend in financial performance despite ongoing losses.
- Cash Position: As of March 31, 2026, the company had $466.0 million in cash and cash equivalents, a significant increase from $149.6 million as of December 31, 2025, demonstrating substantial progress in cash management.
- Debt Increase: The company's debt stood at $50.5 million as of March 31, 2026, up from $31.6 million as of December 31, 2025, reflecting increased financing needs as the company expands its operations.
- Financial Guidance: COMPASS expects its current cash position to be sufficient to fund operating expenses and capital expenditures through 2028, showcasing confidence in its future stability and growth prospects.
See More
Compass Pathways Secures FDA NDA Rolling Review Approval
- Regulatory Acceleration: The FDA has granted Compass a rolling submission and review request for its NDA based on positive Phase 3 data for COMP360, with the final submission on track for Q4 2026, thereby expediting the drug's market entry for treatment-resistant depression.
- Strong Financial Position: Compass reported cash and cash equivalents of $466 million as of Q1 2026, a significant increase from $149.6 million at the end of 2025, ensuring sufficient funding for operations and supporting its commercialization efforts well into 2028.
- Promising Clinical Data: COMP360 has demonstrated significant clinical effects in three large late-stage trials, with 26-week Part B data expected to be released in early Q3 2026, which will further enhance market anticipation and confidence in the drug's efficacy.
- Commercial Readiness: Compass has assembled a highly experienced commercial leadership team and is advancing comprehensive launch preparedness efforts, including education initiatives with key opinion leaders and healthcare providers, ensuring that COMP360 can successfully meet market demands upon launch.
See More
COMPASS Pathways to Announce Q1 Earnings on May 13
- Earnings Announcement: COMPASS Pathways ADS (CMPS) is set to announce its Q1 2023 earnings on May 13 before market open, with a consensus EPS estimate of -$0.45, indicating ongoing challenges in profitability.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen one upward revision and no downward adjustments, reflecting a cautiously optimistic outlook from analysts regarding COMPASS Pathways' future performance, despite the overall negative expectation.
- Market Outlook: The company has reported positive Phase III results for its psilocybin asset in treatment-resistant depression trials, suggesting significant potential value in the mental health sector, which could lay the groundwork for future growth.
- Industry Developments: With Trump signing legislation to expedite PTSD research, COMPASS Pathways is positioned strongly in the rapidly evolving psychedelic market, particularly with its upcoming psychedelic filing, which may attract increased investor interest.
See More
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
